I added more shares of RX.V / BIOYF at C$1.07 and am bidding for more. I'm putting money where my mouth is.
I think you are underestimating how much growth that RX.V will see next year. Remember 5 products vs. 1. Also, people look at both top line and bottom line. Finally, how many companies can you find with this track record of long term revenue growth? The only other companies that I would put in the same category as RX.V are PFHO, PBSV, and INX.V.
Mike
SwingTrade is my favorite board - #board-1781
Due diligence on my favorite stocks is located on the sticky note on the SwingTrade board.